The first ones to get the vaccine, which has been tested and approved for emergency use, would most likely be the people of the country where it has been developed - meaning those in the US and the UK.
Both countries have invested in their candidates (US has invested in Oxford's candidate too) for public distribution after necessary approvals.
Though there is no vaccine candidate from India, the one from Oxford is likely to reach the country.
AstraZeneca, Oxford's partner, has collaborated with the Serum Institute of India, the world's largest vaccine manufacturer by doses, to manufacture/supply a billion doses of its COVID-19 vaccine to India and other low-and-middle-income countries.
Additionally, groups like GAVI are also working to buy doses for developing nations.
Given that the world's population is over 7.8 billion and there will not be those many doses in the initial stages by early 2021, the countries are likely to prioritize the process of vaccination, which will be finalized at a later stage.